{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:20Z","timestamp":1792785440265,"version":"4.5.0"},"reference-count":72,"publisher":"Informa UK Limited","issue":"14","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2018,9,22]]},"DOI":"10.1080\/14656566.2018.1515915","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T03:11:22Z","timestamp":1537758682000},"page":"1623-1629","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-7149","authenticated-orcid":false,"given":"Miquel","family":"Bioque","sequence":"first","affiliation":[{"name":",","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Salud Mental (CIBERSAM), Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[{"name":",","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Salud Mental (CIBERSAM), Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01121-6"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000367776.96012.ca"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.143"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.12.010"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0350-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0485"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S42735"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447050-00004"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796016001025"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2016.1115479"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1191945"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008296.pub2"},{"key":"e_1_3_3_21_1","unstructured":"Janssen. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension prescribing information. Orth-McNeil-Janssen Pharmaceuticals Inc; 2009."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1478727"},{"issue":"5","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0b013e3182966c2f","article-title":"Interaction between paliperidone and carbamazepine","volume":"35","author":"Yasui-Furukori N","year":"2013","unstructured":"Yasui-Furukori N, Kubo K, Ishioka M, et al. Interaction between paliperidone and carbamazepine. Ther Drug Monit. 2013;35(5):649\u2013652.","journal-title":"Ther Drug Monit"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.4137\/JCNSD.S1607"},{"key":"e_1_3_3_25_1","unstructured":"Food and Drug Administration. FDA webpage. 2016 [cited 2018 Aug 21]. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2017.1404112"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs099"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S63948"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.79"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125311413006"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-79"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-10-12"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.001"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001076"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.014"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.11.006"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S77778"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000195"},{"key":"e_1_3_3_42_1","unstructured":"European Medicines Agency. European public assessment report. 2018 [cited 2018 Aug 21]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004066\/human_med_001829.jsp&mid=WC0b01ac058001d124"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1085849"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0416-1"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13050"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.597"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1359516"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.122"},{"issue":"4","key":"e_1_3_3_51_1","first-page":"222","article-title":"Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent","volume":"41","author":"Daghistani N","year":"2016","unstructured":"Daghistani N, Rey JA. Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent. Pharmacy and Therapeutics. 2016;41(4):222\u2013227.","journal-title":"Pharmacy and Therapeutics"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000190"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11308"},{"key":"e_1_3_3_54_1","doi-asserted-by":"crossref","unstructured":"Mathews M Gopal S Singha A et al. A comparison of schizophrenia relapse rates of 3 paliperidone formulations once-daily once-monthly and once every-3-month: post hoc analysis from 3 randomized controlled trials (Poster) in Schizophrenia International Research Society Meeitng; Firenze Italy; 2018.","DOI":"10.1093\/schbul\/sby016.321"},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"Mathews M Gopal S Singha A et al. Comparison of paliperidone palmitate 3-month and paliperidone palmitate 1-month formulation for negative symptoms in schizophrenia: a phase 3 non-inferiority study (Poster) in Schizophrenia International Research Society Meeting; Firenze Italy; 2018.","DOI":"10.1093\/schbul\/sby017.761"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1288716"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S114172"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-017-0025-5"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1351370"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1363050"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913001016"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s05"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s02"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-7006(13)70107-6"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0270"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2015.05.014"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20446"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109104882"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.07.007"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0348-x"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S85514"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0050-0"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1184156"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2018.1515915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:04:09Z","timestamp":1772759049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2018.1515915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":72,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,9,22]]}},"alternative-id":["10.1080\/14656566.2018.1515915"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2018.1515915","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}